This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n5http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11110%2F13%3A10196439%21RIV15-MSM-11110___/
n18http://localhost/temp/predkladatel/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n12http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n10http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11110%2F13%3A10196439%21RIV15-MSM-11110___
rdf:type
n17:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1200/JCO.2012.41.6180
dcterms:description
Purpose: This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine whether the overall survival (OS) benefit with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with myeloma who were ineligible for transplantation was maintained after 5 years of follow-up and to explore the risk of second primary malignancies. Conclusion: VMP resulted in a significant reduction in risk of death versus MP that was maintained after 5 years' follow-up and despite substantial use of novel-agent-based salvage therapies. There is no emerging safety signal for second primary malignancies following VMP. Purpose: This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine whether the overall survival (OS) benefit with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with myeloma who were ineligible for transplantation was maintained after 5 years of follow-up and to explore the risk of second primary malignancies. Conclusion: VMP resulted in a significant reduction in risk of death versus MP that was maintained after 5 years' follow-up and despite substantial use of novel-agent-based salvage therapies. There is no emerging safety signal for second primary malignancies following VMP.
dcterms:title
Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
skos:prefLabel
Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
skos:notation
RIV/00216208:11110/13:10196439!RIV15-MSM-11110___
n3:aktivita
n14:N
n3:aktivity
N
n3:cisloPeriodika
4
n3:dodaniDat
n10:2015
n3:domaciTvurceVysledku
n7:1988050
n3:druhVysledku
n13:J
n3:duvernostUdaju
n11:S
n3:entitaPredkladatele
n5:predkladatel
n3:idSjednocenehoVysledku
95851
n3:idVysledku
RIV/00216208:11110/13:10196439
n3:jazykVysledku
n16:eng
n3:klicovaSlova
PHASE-III; ACUTE-LEUKEMIA; INDUCTION THERAPY; CYTOGENETIC ABNORMALITIES; RANDOMIZED-TRIAL; PLUS THALIDOMIDE; ELDERLY-PATIENTS; LONG-TERM SURVIVAL; INTERNATIONAL STAGING SYSTEM; STEM-CELL TRANSPLANTATION
n3:klicoveSlovo
n4:RANDOMIZED-TRIAL n4:INTERNATIONAL%20STAGING%20SYSTEM n4:PHASE-III n4:PLUS%20THALIDOMIDE n4:ACUTE-LEUKEMIA n4:ELDERLY-PATIENTS n4:LONG-TERM%20SURVIVAL n4:STEM-CELL%20TRANSPLANTATION n4:CYTOGENETIC%20ABNORMALITIES n4:INDUCTION%20THERAPY
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[CD19FFE1D544]
n3:nazevZdroje
Journal of Clinical Oncology
n3:obor
n19:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
22
n3:rokUplatneniVysledku
n10:2013
n3:svazekPeriodika
31
n3:tvurceVysledku
Dimopoulos, Meletios A. Schlag, Rudolf San Miguel, Jesus F. Deraedt, William Delforge, Michel Mateos, Maria-Victoria Špička, Ivan Richardson, Paul G. Shpilberg, Ofer Anderson, Kenneth C. Liu, Kevin Palumbo, Antonio Samoilova, Olga S. Kropff, Martin Jiang, Bin van de Velde, Helgi Esseltine, Dixie-Lee Cakana, Andrew Khuageva, Nuriet K. Petrucci, Maria Teresa Dmoszynska, Anna Abdulkadyrov, Kudrat M.
n3:wos
000314099800012
s:issn
0732-183X
s:numberOfPages
8
n12:doi
10.1200/JCO.2012.41.6180
n18:organizacniJednotka
11110